Rice lab’s injectable gel feeds steady dose of drugs to tumor cells
An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
The Latest on: Cancer immunotherapy
- Astellas Acquires Collaboration Partner Potenza Therapeutics, Adding Cancer Immunotherapy Programs on December 17, 2018 at 7:15 am
Astellas Pharma has acquired Potenza Therapeutics for up to $404.7 million in a deal that bolsters the buyer’s cancer immunotherapy pipeline—more than three years after the companies launched an immun... […]
- Global Cancer Immunotherapy Market Outlook Market Dynamics on Mounting Demand, Technological Advancements and Geography in-Depth 2017-2026 on December 15, 2018 at 4:57 am
New York, NY -- (SBWIRE) -- 12/15/2018 -- A new research by MarketResearch.Biz on Cancer Immunotherapy gives complete guidance which provides the most recent Cancer Immunotherapy market patterns like ... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market is grow with 14.0% CAGR during the forecast time period 2018-2026 on December 14, 2018 at 3:21 am
The global cancer immunotherapy drug discovery outsourcing market size is anticipated to around USD 1.8 billion by 2026, this market is anticipated to grow with 14.0% CAGR during the forecast time per... […]
- Can we teach the immune system to fight cancer? on December 13, 2018 at 3:52 pm
T cells attacking cancer (royaltystockphoto). When telling the story of immunotherapy and cancer and how the two battle it out, it’s awfully challenging not to pull out the old A Tale of Two ... […]
- Immunotherapy Changes Early-Stage Urothelial Treatment and Practice on December 11, 2018 at 11:14 am
Two-year follow-up data from the phase III trial showed sustained improvements in OS with pembrolizumab (Keytruda) over chemotherapy in pretreated patients with locally advanced or recurrent urothelia... […]
- Global Dendritic Cell Cancer Immunotherapy Vaccine Market Sales Dosage Price and Clinical Trials Outlook 2024 on December 6, 2018 at 1:09 am
Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-dosage-price-and-clinical-trials-outlook-2024.php Conventional therapies like surgery, radiotherapy an... […]
- Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer on December 5, 2018 at 3:04 pm
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer. Immunotherapy has shown benefit in some patients with ... […]
- New Cancer Immunotherapy Approach Turns Immune Cells into Tiny Anti-Tumor Drug Factories on December 4, 2018 at 1:21 pm
Cancer immunotherapy — efforts to better arm a patient’s own immune system to attack tumors — has shown great potential for treating some cancers. Yet immunotherapy doesn’t work for everyone, and some ... […]
- New cancer immunotherapy approach turns human cells into tiny anti-tumor drug factories on December 4, 2018 at 12:30 pm
UC San Diego School of Medicine researchers developed a method to use B cells to manufacture and secrete microRNA-containing vesicles and showed they can inhibit tumor growth in mice. Credit: UC ... […]
- Global Cancer Immunotherapy Market 2017-2027 Featuring Leading Players - Pfizer, Merck, Amgen and Roche on December 4, 2018 at 10:09 am
The "Cancer Immunotherapy Market" report has been added to ResearchAndMarkets.com's offering. The global Cancer Immunotherapy market reached USD 42,584.18 Million in 2017 by registering a CAGR of 7.5% ... […]
via Google News and Bing News